<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="58742">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01960634</url>
  </required_header>
  <id_info>
    <org_study_id>GEM-1304</org_study_id>
    <secondary_id>GEM-1304</secondary_id>
    <nct_id>NCT01960634</nct_id>
  </id_info>
  <brief_title>Translational Study for BRAFV600 Serum and Plasma Determination in Patients With BRAFV600 Metastatic Melanoma</brief_title>
  <acronym>BRAFV600</acronym>
  <official_title>Translational Study for BRAFV600 Serum and Plasma Determination in Patients With BRAFV600 Metastatic Melanoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Grupo Español Multidisciplinar de Melanoma</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Grupo Español Multidisciplinar de Melanoma</source>
  <oversight_info>
    <authority>Spain: Comité Ético de Investigación Clínica</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multi-centric translational study with biological samples collection. The aim of
      this study is to validate a method to detect BRAFV600 in blood samples.

      Samples: Blood from patients with BRAFV600 metastatic melanoma collected following standard
      medical practice.

      The treatment is not the aim of the study. Patients can be treated either with specific or
      no-specific drug.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2013</start_date>
  <completion_date type="Anticipated">July 2016</completion_date>
  <primary_completion_date type="Anticipated">April 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Rate of patient in which BRAF V600 in blood samples is present/absent</measure>
    <time_frame>two years</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of patients with BRAFV600 present in tumor sample vs blood sample</measure>
    <time_frame>two years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <other_outcome>
    <measure>BRAF V600 blood levels and illness evolution</measure>
    <time_frame>two years</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>NRAS and p61BRAFFV600 serum levels and clinic evolution</measure>
    <time_frame>two years</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>BRAFV600 blood levels vs progression-free survival</measure>
    <time_frame>two years</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">58</enrollment>
  <condition>Stage IV Skin Melanoma</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Serum and Plasma
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with histologically confirmed melanoma and BRAF V600 mutation
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Confirmed diagnosis of melanoma and BRAFV600

          -  Signed Informed Consent Form

          -  Unresectable phase III or phase IV melanoma

          -  The patients should be starting a treatment for melanoma (either first line or
             subsequent lines)
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>María González Cao, MD</last_name>
    <role>Study Director</role>
    <affiliation>Hospital Universitario Quirón Dexeus</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ana Marquez, Graduate</last_name>
    <phone>+34 934 34 44 12</phone>
    <phone_ext>114</phone_ext>
    <email>ana.marquez@mfar.net</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital Infanta Cristina</name>
      <address>
        <city>Madrid</city>
        <state>Badajoz</state>
        <zip>06080</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Costa del SOl</name>
      <address>
        <city>Marbella</city>
        <state>Málaga</state>
        <zip>29603</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elisabet Pérez, MD</last_name>
      <email>eliperu@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Elisabet Pérez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital del Mar</name>
      <address>
        <city>Barcelona</city>
        <zip>08003</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Quirón Dexeus</name>
      <address>
        <city>Barcelona</city>
        <zip>08028</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>María González Cao, MD</last_name>
      <email>mgonzalezcao@oncorosell.com</email>
    </contact>
    <investigator>
      <last_name>María González Cao, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Marques de Valdecilla</name>
      <address>
        <city>Santander</city>
        <zip>39008</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Almudena García, MD</last_name>
      <email>algarcia@humv.es</email>
    </contact>
    <investigator>
      <last_name>Almudena García, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Virgen de la Salud</name>
      <address>
        <city>Toledo</city>
        <zip>45004</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fundación Instituto Valenciano de Oncología</name>
      <address>
        <city>Valencia</city>
        <zip>46009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marisa</last_name>
      <email>datamanager5@fincivo.org</email>
    </contact>
    <investigator>
      <last_name>Virtudes Soriano, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Miguel Servet</name>
      <address>
        <city>Zaragoza</city>
        <zip>50009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Conchi Velazquez</last_name>
      <email>cvelazquez.miguelservet@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Teresa Puértolas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 11, 2014</lastchanged_date>
  <firstreceived_date>October 7, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
